Vyloy Approval in Korea Faces Reimbursement Hurdles Despite Clinical Promise
• Vyloy (zolbetuximab), the first Claudin 18.2-targeted gastric cancer drug, has been approved in Korea for advanced gastric cancer treatment.
• Concerns arise that Korea's reimbursement system may impede patient access to Vyloy, despite its potential to significantly improve survival rates.
• The Health Insurance Review and Assessment Service (HIRA) is reviewing the companion diagnostic device (CDx) for Claudin 18.2, potentially delaying Vyloy's launch.
• Experts advocate for policy improvements to support the synchronized introduction of targeted drugs and their companion diagnostics in Korea.
© Copyright 2025. All Rights Reserved by MedPath